Literature DB >> 12721334

Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?

Hanns Ulrich Zeilhofer1, Girolamo Calò.   

Abstract

The neuropeptide nociceptin, also called orphanin FQ (N/OFQ), is the endogenous agonist of the N/OFQ peptide receptor (NOP receptor). Both N/OFQ and the NOP receptor share a high degree of homology with classical opioid peptides and opioid receptors, respectively, and use similar signal transduction pathways as classical opioids. The NOP receptor has thus been regarded as the fourth member of the opioid receptor family. Despite this close relationship, 7 years of research have demonstrated that the N/OFQ system has a distinct pharmacological profile and serves different physiological functions. In particular, its role in the control of pain and analgesia at different levels of integration appears quite different from that of classical opioids. The recent development of specific antagonists at the NOP receptor and of NOP receptor or N/OFQ precursor knock-out mice have generated new insights into the role of N/OFQ in pain processing and help to evaluate the N/OFQ-NOP system as a potential target for new analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721334     DOI: 10.1124/jpet.102.046979

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.

Authors:  Massimo Ibba; Masato Kitayama; John McDonald; Girolamo Calo; Remo Guerrini; Judit Farkas; Geza Toth; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-21       Impact factor: 3.000

3.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

Review 4.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

5.  Opioid-related (ORL1) receptors are enriched in a subpopulation of sensory neurons and prolonged activation produces no functional loss of surface N-type calcium channels.

Authors:  Swetha S Murali; Ian A Napier; Beth K Rycroft; MacDonald J Christie
Journal:  J Physiol       Date:  2012-02-27       Impact factor: 5.182

6.  Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.

Authors:  Mei-Chuan Ko; Norah N Naughton
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice.

Authors:  Tomohiro Koyama; Kazuhiko Fukuda
Journal:  J Anesth       Date:  2009-05-15       Impact factor: 2.078

9.  Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.

Authors:  Taline V Khroyan; Willma E Polgar; Juan Orduna; Faming Jiang; Cris Olsen; Lawrence Toll; Nurulain T Zaveri
Journal:  Eur J Pharmacol       Date:  2009-03-12       Impact factor: 4.432

10.  Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad?

Authors:  Laura Micheli; Elena Lucarini; Francesca Corti; Roberto Ciccocioppo; Girolamo Calò; Anna Rizzi; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Eur J Pharmacol       Date:  2018-01-31       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.